stub DEA Adjusts 2024 Drug Production Quotas, Increasing Emphasis on THC, Psilocybin, and DMT for Research -
Connect with us


DEA Adjusts 2024 Drug Production Quotas, Increasing Emphasis on THC, Psilocybin, and DMT for Research

Updated on

The Drug Enforcement Administration (DEA) has revised its proposed production quotas for 2024, increasing the amounts of THC, psilocybin, and DMT for research purposes. This adjustment follows comments from registered manufacturers seeking higher quotas to meet medical and scientific needs. The final order, set to be published in the Federal Register, nearly doubles the quotas for delta-9 THC and other tetrahydrocannabinol. Psilocybin sees an increase from 15,000 to 20,000 grams, while DMT increases from 3,000 to 11,000 grams.

The production goals for marijuana and various psychedelics remain consistent with the initial proposals from November 2023. Notably, the quotas align with the DEA's 2023 production levels, reflecting the increasing interest in the therapeutic potential of cannabis and psychedelics. The DEA acknowledges a surge in the use of Schedule I hallucinogenic substances for research and clinical trials, attributing it to new registration applications from researchers and manufacturers.

Comments requesting increases in psychedelic production quotas for “religious use” prompted DEA's response, emphasizing that production quotas are determined based on individual manufacturing quota requests. The agency did not directly address a request for a hearing but mentioned its engagement with indigenous communities and welcomed further input.

In response to suggestions to include natural components in production quotas, DEA clarified its adherence to the Controlled Substances Act, setting quotas based on individual constituents of psilocybin, psilocyn, and mescaline, both synthetically and naturally derived.

DEA's monopoly on marijuana production for research purposes ended in 2022, potentially aiding higher production quotas. The finalized 2024 quotas are part of an ongoing administrative review of cannabis scheduling, following a recommendation to move marijuana from Schedule I to Schedule III under the CSA. Simultaneously, the FDA considers authorizing MDMA for PTSD treatment based on clinical trial efficacy.

While DEA emphasizes its support for rigorous research, it faces criticism for actions perceived as hindering studies, including attempts to ban certain psychedelics. Advocates and scientists express concern over these actions, emphasizing the therapeutic potential of these compounds.

In a separate development, a federal appellate panel denies a motion to reschedule psilocybin under the CSA, and DEA warns Georgia pharmacies against dispensing THC, remaining a Schedule I drug despite the state's allowance for medical marijuana sales.

This story was originally published by Marijuana Moment.


Warning: Trying to access array offset on value of type bool in /home/customer/www/ on line 830

Warning: Attempt to read property "taxonomy" on null in /home/customer/www/ on line 830